A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells

Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling

(2013) Susan Thrane et al.   BREAST CANCER RESEARCH AND TREATMENT

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

(2013)   LANCET

Breast cancer: Current and future endocrine therapies

(2013) Carlo Palmieri et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERα in breast cancer

(2013) X Q Zheng et al.   ONCOGENE

Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients

(2012) Wulf Siggelkow et al.   BMC CANCER

NFκB signaling is important for growth of antiestrogen resistant breast cancer cells

(2012) Christina W. Yde et al.   BREAST CANCER RESEARCH AND TREATMENT

Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers

(2012) Rita Nahta et al.   BREAST CANCER RESEARCH AND TREATMENT

Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer

(2012) H R Ali et al.   BRITISH JOURNAL OF CANCER

A Competitive Stapled Peptide Screen Identifies a Selective Small Molecule that Overcomes MCL-1-Dependent Leukemia Cell Survival

(2012) Nicole A. Cohen et al.   CHEMISTRY & BIOLOGY

Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis

(2011) H. Sun et al.   BLOOD

Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment

(2011) S C Drury et al.   ENDOCRINE-RELATED CANCER

Epidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancer

(2011) E P Booy et al.   ONCOGENE

Deubiquitinase Inhibition by Small-Molecule WP1130 Triggers Aggresome Formation and Tumor Cell Apoptosis

(2010) V. Kapuria et al.   CANCER RESEARCH

Lapatinib Restores Hormone Sensitivity with Differential Effects on Estrogen Receptor Signaling in Cell Models of Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer with Acquired Endocrine Resistance

(2010) A. F. Leary et al.   CLINICAL CANCER RESEARCH

Mcl-1; the molecular regulation of protein function

(2010) Luke W. Thomas et al.   FEBS LETTERS

Aurora Kinase Inhibitors - Rising Stars in Cancer Therapeutics?

(2010) A. A. Dar et al.   MOLECULAR CANCER THERAPEUTICS

FOXA1 is a key determinant of estrogen receptor function and endocrine response

(2010) Antoni Hurtado et al.   NATURE GENETICS

Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines

(2010) H Zhang et al.   ONCOGENE

An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer

(2009) Katrine L. Henriksen et al.   ACTA ONCOLOGICA

Breast cancer cells can switch between estrogen receptor α and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance

(2009) Katrine Sonne-Hansen et al.   BREAST CANCER RESEARCH AND TREATMENT

The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise

(2008) Susanne Møller et al.   ACTA ONCOLOGICA

Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant

(2008) Thomas Frogne et al.   BREAST CANCER RESEARCH AND TREATMENT

Bcl-2 inhibitors: small molecules with a big impact on cancer therapy

(2008) M Vogler et al.   CELL DEATH AND DIFFERENTIATION

ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2

(2008) S. Pancholi et al.   ENDOCRINE-RELATED CANCER

The regulatory β-subunit of protein kinase CK2 regulates cell-cycle progression at the onset of mitosis

(2008) C W Yde et al.   ONCOGENE

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial

(2007) Birgitte B Rasmussen et al.   LANCET ONCOLOGY